GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Resverlogix Corp (FRA:RFS) » Definitions » Dividend-Payout-to-FFO

Resverlogix (FRA:RFS) Dividend-Payout-to-FFO


View and export this data going back to 2005. Start your Free Trial

What is Resverlogix Dividend-Payout-to-FFO?

Dividend-Payout-to-FFO only applies to REITs.


Resverlogix (FRA:RFS) Business Description

Traded in Other Exchanges
Address
4820 Richard Road South West, Suite 300, Calgary, AB, CAN, T3E 6L1
Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with chronic disease including cardiovascular disease (CVD) and associated comorbidities, and COVID-19.